29800-89-3 Usage
General Description
Methyl isonicotinate is an organic compound and a derivative of isonicotinic acid. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. This chemical is known for its characteristic odor and is soluble in organic solvents such as ethanol and acetone. Methyl isonicotinate is also used as a flavoring agent in the food industry and as a fragrance ingredient in perfumes and other personal care products. Its chemical properties make it a valuable compound for a variety of industrial and commercial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 29800-89-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,8,0 and 0 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 29800-89:
(7*2)+(6*9)+(5*8)+(4*0)+(3*0)+(2*8)+(1*9)=133
133 % 10 = 3
So 29800-89-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H9NO2/c1-11-8(10)6-7-2-4-9-5-3-7/h2-5H,6H2,1H3
29800-89-3Relevant articles and documents
-
Grollmann et al.
, p. 885 (1971)
-
NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
-
Page/Page column 37, (2020/05/29)
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Paragraph 1253; 1254, (2014/07/23)
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.